Following the approval of INTERCEPT®, the conversion from conventional platelets to INTERCEPT® platelets can be divided into the five categories in this module series.
This first module will outline key implementation steps required to be able to receive, dispense and transfuse INTERCEPT® platelets in your hospital.
Suggestions for key staff to include on your implementation team, general background information about INTERCEPT® platelets, and a basic implementation checklist to assist in your project planning are included.
Decisions regarding Implementing INTERCEPT® (Module 1); Platelet Logistics and Policy Updates (Module 2); Getting Your IT systems Ready (Module 3); Platelet Bag Handling Recommendations (Module 4); and Hospital Staff Education (Module 5) in this educational series are based on the following key points:
- INTERCEPT® Blood System for Platelets reduces transfusion transmitted infection (TTI) risk, including sepsis.1,2
- INTERCEPT® or pathogen reduced platelets are FDA approved as an alternative to gamma irradiation and meet the AABB standards as a CMV mitigation strategy.2
- Pathogen reduced platelets can be used for all patients receiving platelet units.2, 3
Many of onboarding steps can be done concurrently to shorten the implementation time frame. Upon completion of the implementation steps outlined in this module series, there is no further work to do for the use of INTERCEPT® platelets at your hospital.
We are here to help. The information reviewed in this module series is also available in our hospital implementation guide.
The Cerus Hospital Affairs team has experience with hundreds of hospitals in onboarding INTERCEPT® platelets. A member of this team is available to provide the support you need.
Once you have reviewed the implementation support materials in this module series and would like further assistance, please email us at firstname.lastname@example.org for help with any part of the INTERCEPT® onboarding process.
- 1 FDA. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion: Guidance for Industry.In: CBER, ed. Silver Spring, MD: US Food and Drug Administration; 2019.
- 2 INTERCEPT Blood System for Platelets [Package Insert]. Concord, CA: Cerus Corporation; July 17, 2018.
- 3 http://www.aabb.org/sa/standards/Pages/standards-programs.aspx
Cynthia Robbins, RPh BSPharm
Senior Director, Education and Training Cerus Corporation
Cynthia Robbins RPh BSPharm earned her BS Pharmacy at the University of Medical Center at Chicago. Cynthia has over twenty-five years of experience in blood safety and the blood products fractionation industry. In her current role, Cynthia is focused on educating hospital clinicians in transfusion medicine and blood banking, as well as other specialty clinicians who utilize blood products for their patients on the importance of blood safety and pathogen reduction.